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ABSTRACT
A COMPUTATIONAL MODEL FOR TRANSDERMAL DIFFUSION
OF LIDOCAINE AND TETRACAINE TOPICAL PATCHES
By
Qian Dong
In recent years, transdermal drug delivery patches (TDDP) have developed rapidly. This is
because the TDD system has more advantages than traditional drug delivery systems such
as oral medicine and intravenous injection. In order to reach the circulatory system of the
human body, drug molecules have to pass through the epidermis (outer layer) of the skin.
The barrier properties of epidermis originate from low permeability of stratum corneum
(SC) which is the outermost layer of the human skin. The objective of this thesis is to build
a Finite Element (FE) model, utilizing commercial FE software (ANSYS), that can be
implemented to estimate parameters of diffusion as well as common diffusion cell
experiments. Use of the regular geometry, “brick and mortar”, to simulate tortuous
intercellular route of SC is presented. It is assumed that diffusion occurs only within the
SC lipids and the lipids are isotropic. The steady-state flux and lag time are solved and
compared with the analytical results.
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CHAPTER 1
INTRODUCTION

1.1 Objective

The transdermal drug delivery (TDD) system represents a new method to replace oral
delivery of drugs and hypodermic injection. Although the TDD system is not a perfect
alternative to traditional drug delivery methods (oral delivery or hypodermic injection), it
has made an important contribution to medical practice. For thousands of years, people
have already placed substances on the human skin for therapeutic effects such as traditional
Chinese medicated bath [2], and, in the modern era, a variety of topical patches have been
developed to treat chronic diseases. In ancient China, transdermal drug delivery system has
been one of the ways for external treatment. Treatment of a variety of diseases includes
dermatosis, rheumatism, joint pain, and others. The drug administered directly to the lesion
site has less toxic side effects. In the modern era, the first transdermal system for systemic
delivery consisted of a three-day patch that delivered scopolamine to treat motion sickness,
and was approved for use in the United States in 1979. A decade later, nicotine patches
became the first transdermal blockbuster, which raised the profile of transdermal delivery
systems in medicine, in particular and for the public in general. With the development of
transdermal drug delivery systems, TDD has already been developed for three generations
[1-4]. Between 1979 and 2007, numerous transdermal drugs have been approved by the
1

FDA each year (Figure 1.1).

Figure 1.1 Cumulative number of transdermal drugs approved by the FDA since 1979.
Source: The FDA Orange Book.

Currently, in an effort to advance TDD systems, transdermal drug delivery patches
(TDDP) are being mainly fabricated. The nicotine patches have been mentioned widely in
the literature [4-6], but it is important to notice that these are typical first generation
transdermal patches with choice of special drugs. The use of TDDP significantly reduces
major drawbacks that are associated with oral medicine, intravenous injection and
intramuscular injection, such as viscera stimulation from oral medicine or increasing
infection risk by injection. It reduces pain and inflammation while propagating quicker
regeneration of tissues; and also it can avoid high percentage of protein related medicines
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that can be influenced by the digestive system; moreover, unlike intravenous injection,
optimal transdermal systems can slowly release medicine in the form of particles to the
blood stream so as to avoid many undesired side effects.
Aside from these comparisons, the TDD still faces a big barrier of human skin.
Thus, this study focuses on the use of commercial finite element analysis (FEA) software,
ANSYS, to build a computational model for predicting diffusion in transdermal drug
delivery patches. The FE results, which are much more conventional, are predicted by
changing few parameters in the FEA model. This computational model can help the TDDP
designers to choose ideal parameters for transdermal drug delivery experiments so that
precious time and expense can be saved from performing long time experiments.

1.2 Background Information
1.2.1 Skin Structure
The skin is a remarkable organ of the body which is able to perform various functions. Skin
is not only a protective barrier against mechanical, thermal and physical injury and
potential exposure to hazardous substances, but also has many other functions such as
absorption, permeability, secretion, excretion and immunity.
The skin is a variably lamellar structure, which not only includes three main
components, epidermis, dermis and subcutaneous layer, but also includes several substructure at three main components as shown in Figure (1.2). Skin is constantly being

3

regenerated by new cell fission from the bottom layer of the skin to the top layer, because
the bottom layers have the blood supply. The main function of epidermis is to form a tough
barrier against the outside world, which has the primary obstacle to transdermal drug
delivery. The dermis is the middle layer of the skin located between the epidermis and the
subcutaneous layer, which is responsible for the structural integrity of the human skin. The
subcutaneous layer includes numerous fat cells for isolating cold and trauma from outside
to the underlying layer.

Figure 1.2 The structure of human skin which includes three main parts – epidermis,
dermis and subcutaneous layer. In each layer, they have different low-level structure.
Source: Falcone, R., Jaffe, M., Ravindra, N.M., New screening methodology for selection of polymeric
matrices for transdermal drug delivery devices, Bioinspired, Biomimetic and Nanobiomaterials, Volume 2
Issue BBN2, p. 65-75, 2013.

1.2.1.1 Components of Epidermis

The epidermis is the outermost layers of the human

skin [8]. The epidermis has 5 low-level layers which have different cell arrangement and
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components. Figure 1.3 shows different cell arrangement in the epidermis layers. (1)
Stratum basal is the bottom layer of epidermis. The cells in this layer can constantly
reproduce so as to get constantly pushed up into the next layer. (2) Stratum spinosum layer
can prevent bacteria from entering the cells and the moisture being lost. The cells of this
layer can also reproduce. (3) Stratum granulosum can produce a protein, keratin, which is
found in nail and hair. The cells, in this layer, cannot reproduce themselves. (4) Stratum
lucidum layer plays the role of cushioning and protection and is found only on the palms
of hands and soles of feet. (5) Stratum corneum is the outer-layer of skin which forms the
primary barrier to drug transport.

Figure 1.3 shows the schematic image of the epidermis with its sub structure such as the
stratum basale layer, the stratum spinosum layer, the stratum granulosum layer, the stratum
lucidum layer and the stratum corneum layer. The stratum corneum layer directly contacts
with external environment.
Source: Marks, J.G., Miller, J., Lookingbill and Marks' Principles of Dermatology (4th ed.), Elsevier, p. 1–
7. ISBN 1-4160-3185-5, 2006.
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1.2.1.2 Stratum Corneum (SC) The outer 10-15 micrometer of skin, called stratum
corneum, is a dead tissue that forms primary barrier to drug transport, since stratum
corneum is a composite material made of protein and lipids structurally organized as “brick
and mortar”, as shown in Figure 1.3. The hydrophobic lipid bi-layers fill all of extracellular
spaces, where this lipid-enriched matrix is organized into lamellar membranes that
surround the corneocytes. The lipid-enriched matrix of the stratum corneum includes not
only the structure that limits transdermal delivery of hydrophobic drug, but also the socalled stratum corneum “reservoir”, within which lipid soluble drugs, such as topical
corticosteroids, can accumulate and be slowly released [6]. Therefore, once hydrophobic
medicine can successfully pass through stratum corneum, they get into the viable epidermis
layer which has live cells and nerves but not vessels; it can diffuse rapidly through deeper
tissue and be taken up by the underlying capillaries for systemic administration [10].

6

Figure 1.4 The SC layer consists by corneocytes which are like scaffold for SC structure,
and extracellular hydrophobic matrix.
Source: Sebastien Henry, D., V.M., Mark, G.A. and Mark, R.P., Microfibricated Microneedles: A Novel
Approach to Transdermal Drug Delivery, Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998.

Although the corneocytes (Figure 1.4) contribute volume to be a scaffold for the
stratum corneum structure, modern transdermal delivery strategies focus primarily on
manipulations of the extracellular lipid milieu. The reason why hydrophilic drugs have
exceptional low permeability to cross stratum corneum is the consequence of several
characteristics of the lipid-enriched, extracellular matrix, including its organization into a
highly complicated and tortuous diffusion pathway, such as mortar between bricks,
imposed by geometrically arrayed corneocyte “spacers” [6]. Furthermore, not only the
stranger pathway of bilayers’ extracellular lipids, but also the three extreme hydrophobic
components, ceramide fatty acid and cholesterol, of lipid contribute to the barrier function,
as shown in Figure 1.5.

7

Figure 1.5 The structure of the major components of the stratum corneum intercellular
lipids. Numbers 1 to 8 are ceramides and represent a thin layer with chromatographic
mobility, with ceramide 1 being the least polar and ceramide 8, the most polar. The letters
in square brackets are the structural classifications of the ceramide as suggested by Motta
et al.
Source: Biochim Biophys Acta 1993;1182: 145-51.

1.2.2 Transdermal Patches
Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a
specific dose of medication through the skin and into the bloodstream. An advantage of
transdermal patch over other types of delivery of medication is that the patch provides a
controlled release of the medication into the patient. The main disadvantage to transdermal
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delivery systems stems from the fact that the skin is a very effective barrier; as a result,
only medications whose molecules are small enough to penetrate the skin can be delivered
by this method. Nowadays, there are three main generations of transdermal drug delivery
systems. The first generation is a very simple patch which has specific medicinal properties
such as low-molecular weight, lipophilic and efficacious at low doses. Base on Fick’s law,
the driving force of first generation TDD system is only the concentration gradient. The
second generation of transdermal delivery systems already consider that skin permeability
enhancement is needed to expand the scope of transdermal drugs. Thus the second
generation of transdermal delivery systems add an enhancer layer to increase the skin
permeability by reversibly disrupting stratum corneum structure or simply adding more
driving force for transport into the skin such as chemical disruption, iontophoresis and noncavitational ultrasound. The third generation transdermal delivery systems is poised to
make significant impact on drug delivery because it targets its effects to the stratum
corneum [5]. This targeting enables stronger disruption of stratum corneum layer of skin,
while still protecting the deep tissue. For example, the micro-needles are conceptually a
straightforward way to directly penetrate the stratum corneum layer.
Normally, transdermal patches have similar structures. There are four basic layers
for the common transdermal patches as shown in Figure 1.6. Clear backing layer isolates
other layers from contacting with natural environment. Drug reservoir layer stores the
medicinal particles. Drug delivery membrane layer controls the ratio of drug actives in the
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form medicinal particles. Contact adhesive layer directly attaches to the skin. Based on
different patches, which have different enhancers to increase the diffusion of medicine into
the skin, different layer for enhancers are added. In this study, the author uses SYNERA
Lidocaine and Tetracaine topical patches. These patches have extra integrated heating
component layer for increasing drug diffusion rate by additional temperature gradient,
which can heat the patch and skin surface to 42 °C at room temperature. Therefore, the
SYNERA patch has an additional enhancer layer between the clear backing layer and the
drug reservoir.

Figure 1.6 Common transdermal patch structure which includes four basic layers such as
(i) clear backing layer, (ii) drug reservoir layer, (iii) drug-release membrane layer and (iv)
contact adhesive layer.
Source:(http://drugdelivery.chbe.gatech.edu/Papers/2012/Prausnitz%20Derm%20Book%20Chapter%20201
2.pdf) Accessed on March 15, 2016.
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1.2.3 ADME/T Mechanism
ADME/T mechanism is abbreviation in pharmacokinetic and pharmacology for absorption,
distribution, metabolism, excretion and toxicity, and describes the disposition of a
pharmaceutical compound within an organism. The five criteria already describe all
influences when particles of drug/drug actives touch and interact with human tissues.
Nowadays, although drug designers can synthesize many different kinds of drugs which
have different chemical components, 95% of them cannot be directly used in clinical trials,
because of insufficient ADME/T properties.
1.2.3.1 Toxicity Arguably, drug toxicity is the most challenging drug property that
remains one of the most significant reasons for many drugs failing to reach the market and
for many drugs not approved to the market and withdrawal from the market during the latestage of drug development [12]. Base on individual differences, drug toxicity may occur
from any sources inside the human body such as receptor or enzyme and DNA interaction.
In this study, the anesthetic agents, Lidocaine and Tetracaine, are high lipophilic particles
whose concentrations need to be controlled below specific number in blood.
1.2.3.2 Excretion

Drug excretion is the process whereby a drug molecule is eliminated

by human organs such as liver and kidney. Base on blood flow, protein binding and
lipophilicity, scientists can roughly predict passive excretion [13]. For example, there is
enzyme which can hydrolyze the Tetracaine in the circulatory system. But the renal
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excretion process is more complex due to more than few processes of excretion.
1.2.3.3 Metabolism Compounds begin to break down as soon as they enter the human
body by some enzymes in the liver. As metabolism occurs, the initial (parent) compound
is converted to new compounds called metabolites; and also metabolism can deactivate the
administered dose of parent drug and this usually reduces the effects on the body; moreover,
metabolism may also be pharmacologically active.
1.2.3.4 Distribution Distribution is a transport process by bloodstream which is the main
circulatory system in the human body. Bloodstream delivers drug molecules from areas of
higher concentration to areas of lower concentration. Some factors affecting drug
distribution include regional blood flow rates, drug molecular size, polarity and binding to
serum proteins, forming complex. Sometimes, distribution will face some serious barriers
such as blood brain-barrier.
1.2.3.5 Absorption For a compound to reach a tissue, it usually must be taken into the
bloodstream before being taken up by the target cell. In this study, drug particles/actives
should pass through the stratum corneum layer so as to be taken up into systemic circulation.
Different drug delivery systems have different mucous membranes which also have
different absorption mechanism. Thus, for this study of transdermal drug delivery, the
author will discuss percutaneous absorption.
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1.2.4 Percutaneous Absorption Mechanism
Percutaneous absorption includes entire procedures of drugs delivery from the outermost
layer of the skin to the systemic circulation. This process requires penetration into the
layers of the skin with subsequent permeation across each layer of the skin and finally
uptake to the capillary blood vessel in the upper region of the dermis [13]. In the
percutaneous absorption system, different skin structure will give different routes for drug
passives to diffuse into blood capillary. Thus, processes of passive diffusion of drug
molecules are elaborated in the following model - Figure 1.7.

Figure 1.7 shows that before drug molecules reach systemic circulation, drug molecules
first face partition phenomenon of the skin followed by diffusion through the epidermis
layer.
Source: Alan, B., Ursula, G.R., Pierre, K., Panos, M. Olavi, P., In silico prediction of ADME and
pharmacokinetics, European Journal of Pharmaceutical Sciences, 17, pp. 183-193, 2002.
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1.2.4.1 Routes of Penetration

Absorption via the transdermal route primarily occurs

by passive diffusion through the SC. The rate of diffusion depends on several properties
such as: (1) diffusivity between drug molecules and the SC layer, applied concentration of
drug, surface area of the skin exposed to the drug molecules and the length of diffusion
pathway. Except for the same procedures as shown in Figure 1.7, there are two main routes:
the trans-epidermal route and the trans-follicular route, to penetrate the SC layer. In the
early time periods, chemical particles can penetrate the SC via skin appendages such as
hair follicles, sebaceous glands or sweat glands with absorption through the squamous
epithelial cell lining these structures into the deeper layers of the skin (Figure 1.8).
However, due to large surface areas, trans-epidermal diffusion gradually increases until
dominating penetration processes.
As shown in Figure 1.8, there are two other sub-pathways for the trans-epidermal
route. The first, the transcellular is the diffusion pathway across corneocytes. The second,
the intercellular contributes a tortuous pathway between corneocytes for lipophilic
molecules. Hence, the permeability of the SC components, lipid protein matrix and
corneocytes, are the most important properties of transdermal delivery systems. In this
study, the anesthetic agents, Lidocaine and Tetracaine, are highly lipophilic. The
octanol/water partition ratio (Kow) of Tetracaine reaches 5370 at pH 7.3; and Kow of
Lidocaine also reaches 182 at pH 7.3. Based on the partition ratio, this study only focuses
on intercellular pathway for anesthetic agent transport. Geometric structure of the

14

intercellular pathway is demonstrated in Figure 1.8.

Figure 1.8 demonstrates two penetration routes for percutaneous absorption. (1) The transappendageal route dominates early when drug particles are put on the skin surface. (2) The
trans-epidermal will gradually dominate instead of the trans-appendageal route.
Source: Alan, B., Ursula, G.R., Pierre, K., Panos, M. Olavi, P., In silico prediction of ADME and
pharmacokinetics, European Journal of Pharmaceutical Sciences, 17, pp. 183-193, 2002.

1.2.4.2 Factors Affecting Drug Permeation

The stratum corneum layer and other

epidermal layers are quite distinct structures [14]. Considering drug diffusion through
epidermis, the drug solution must balance between lipid solubility and aqueous solubility
to handle variable structures of the epidermis. The structure of the SC, brick and mortar,
essentially provides a lipophilic milieu for drug transport whereas the other layers of
epidermis provides a more hydrophilic domain. Therefore, the drug molecules which are
balanced between lipid and water solubility can successfully reach systemic circulation
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without excess partition in different solubility media. Based on partition character, the Potts
& Guy equation (Equation 1.1) describes an empirical equation governing highly lipophilic
compounds which use intercellular pathway to penetrate the SC barrier. Equation (1.1)
shows that the permeability of highly lipophilic compounds mainly relate to the partition
coefficient and molecular weight. Also, Table 1.1 demonstrates that additional factors will
affect the permeability of diffusants.
log k = 0.71log Kow − 0.0061𝑀𝑊 − 2.74

(1.1)

k is the permeability of the diffusant (m/s).
Kow is the partition coefficient of the diffusant.
MW is the molecular weight of the diffusant (g/mol).
Table 1.1 Factors Affecting Drug Permeation
(a) Variations in skin structure
(b) Sites of application
(c) Hair follicles ( effects of hair or shaving the site of application)
(d) Sweat glands
(e) Effect of age, blood supply, body temperature and composition (e.g. elevated
body temperature, hyperthyroidism & inflammation etc.)
(f) First pass metabolism by the skin
(g) Ability of the skin to act as a reservoir for transdermal agents
(h) Physicochemical characteristics of the transdermal agents (the ideal
compounds are low molecular weight, lipophilic, soluble in oil & water and have
a high partition coefficient and melting point)
(i) Drug stability
(j) Use of solvent carriers or vehicles
(k) Use of penetration enhancers ( nature & type)
(l) Use of delivery devices etc.
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1.2.5 Diffusion
Diffusion refers to the process by which molecules intermingle as a result of their kinetic
energy (In physics, the kinetic energy of an object is the energy that it possesses due to
motion.) due to random motion. Therefore, the diffusion motion does not come from any
outside force, but more as result of the random distribution of atoms being mixed. By
definition, the atomic motion due to diffusion is random. However, a selective diffusion
process, called osmosis, is driven by the internal energy of the solvent molecule so that the
random diffusion has direction of molecule movement. This internal energy based driving
force is the result from different gradients such as differences in concentration, temperature
or magnetic field. This process was originally evaluated by Adolf Fick in the 19th century
[15], who described this phenomenon by equation (1.2). There are two simple descriptions
of Fick’s law (Table 1.2).
Table 1.2 Description of Fick's Law
1, The molar flux due to diffusion is proportional to the concentration gradient.
2, The rate of change of concentration at a point in space is proportional to the second
derivative of the concentration with space.
1.2.5.1 Fick’s Laws of Diffusion The most common mathematical form of Fick’s laws of
diffusion makes the following assumptions: (i) The receptor phase is a perfect sink. (ii)
Depletion of the donor phase is negligible. (iii) The membrane is homogenous.
𝐽𝑖 = −𝐷𝑖∇𝐶𝑖
The Ji is the molar flux (mol m2s-1) and the Di is the diffusion coefficient (m2s-1).

17

(1.2)

The negative sign of equation (1.2) means that the transport direction of species i
is reversed with concentration gradient, from higher concentration to lower concentration;
moreover, the sign ∇ Ci means the gradient of difference of concentration with distance.
𝜕𝐶𝑖

∇𝐶𝑖 =

𝜕𝑥

(1.3)

From the continuity equation for mass:
𝜕𝐶𝑖
𝜕𝑡

+ ∇C𝑖 = 0

(1.4)

We can derive the Fick’s second law directly:
𝜕𝐶𝑖
𝜕𝑡

= 𝐷𝑖∇2 𝐶𝑖

(1.5)

Equation 1.4 shows a linear equation for the Fick’s second law. Therefore, if this
assumes that 𝐷𝑖 is a constant, the relationship between diffusion concentration and time
can be calculated from the Fick’s second law. However, this assumption is only true in the
dilute solution.

1.2.6 Diffusion Coefficient Prediction Theory
In the above sections, diffusion processes and modern mathematical equations, Fick’s laws
are introduced. In each equation of mass diffusion processes, the diffusion coefficient is
the most important parameter. Therefore, understanding how to calculate the diffusion
coefficient is very important for solving mass diffusion problems [16] [17].

1.2.6.1 Solid Media The diffusion coefficient in solids, at different temperatures, is
generally found to be well predicted by the Arrhenius equation:
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𝐷 = 𝐷0 𝑒 −𝐸𝐴/(𝑘𝑇)

(1.6)

where
𝐷 is the diffusion coefficient (m2/s).
𝐷0 is the maximum diffusion coefficient (at infinite temperature; m2/s).
𝐸𝐴 is the activation energy for diffusion in dimensions of (J atom-1).
T is the absolute temperature (K).
k is the Boltzmann constant.

1.2.6.2 Liquid Media

The diffusion coefficient, as function of temperature, in liquids

can often be found using Stokes-Einstein equation, which predicts that:
𝐷𝑇1
𝐷𝑇2

𝑇 𝜇𝑇2

= 𝑇1
2

𝜇𝑇1

(1.7)

D is the diffusion coefficient (cm2/s).
T is the absolute temperature (K).
T1 and T2 denote temperatures T1 and T2, respectively.
μ is the dynamic viscosity of the solvent (Pa·s).
1.2.6.3 Gas Media

The dependence of the diffusion coefficient on temperature for gases

can be expressed using Chapman- Enskog theory:
𝐷=

1.858∙10−3 𝑇 3/2 √1/𝑀1 +1/𝑀2
2 𝛺
𝑝𝜎12

D is the diffusion coefficient, which is expressed in cm2/s.
1 and 2 index the two kinds of molecules present in the gaseous mixture.
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(1.8)

T is the absolute temperature (K).
M is the molar mass (g/mol).
p is the pressure (atm).
is the average collision diameter (the values are tabulated) (Å).
Ω is a temperature-dependent collision integral (the values are tabulated but usually ~ 1)
(dimensionless).
1.2.6.4 Free Volume Theory In percutaneous drug delivery, if only the intercellular
pathway is considered, the drug molecules will migrate through the extracellular matrix of
the epidermal layer for reaching bloodstream or nerve cells located at the dermis layer. The
extracellular matrix is composed of macromolecular polymers such as proteins. Therefore,
the diffusion of drug molecules can be considered as mobility of small molecules in the
macromolecular matrix. Base on Equation (1.6), the mobility is considerably influenced by
temperature and concentration. However, the extracellular matrix is not common solid
media which can directly use Equation (1.6) for the determination of the diffusion
coefficient. In 1959, Cohen and Turnbull originally suggested an assumption [18] that there
were empty space, called free volume, between molecular sequences, which can be
migration pathways for small hard sphere molecules. In transdermal delivery systems, there
are many factors which will affect the mobility of the drug molecules. However, for
simplifying this case, only free volume concept need to be considered. Therefore, diffusion
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coefficient can be assumed to be proportional to the probability of locating a vacancy of
volume V* or larger and could be written [7].
𝐷 =A𝑒

𝛾𝑉∗
𝑉

(1.9)

V* is the critical volume for migrating molecule.
γ is the overlap factor of free volume.
A is the defined constant which is associated with kinetic energy.
V is the specific volume.
Although, Equation (1.9) already suggests a mathematical method for mobility
based on free volume theory, this is not enough for dealing with problems of drug diffusion
through the skin. Therefore, Vrentas and Duda [19] introduced the following relationship
between more diffusion units and free volume:
𝑉FH =

𝑉∗
𝑤1
𝑤
+ 2
𝑀1𝑗 𝑀2𝑗

(1.10)

VFH is the average hole of free volume.
w1 and w2 represent species 1 and 2.
M1j and M2j are diffusion units.
The above equations clearly indicate that the diffusion coefficient of small
molecules is an exponential function related to free volume; and also the free volume is
related with molecular shape and size. However, Vrentas and Duda [19] further simplified
Equation (1.9) such as the Equation (1.11).
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𝐷 = 𝐷0 𝑒

−

𝐸
𝐾𝑇

𝑒

−𝜉𝑉∗
𝑉

(1.11)

D is diffusion coefficient.
D0 is the pre-exponential factor.
E is the attraction energy between the molecules.
K and T are the Boltzmann’s constant and absolute temperature.
ξ is the ratio of solvent to polymer jumping units.
V* is the critical space of free volume for molecule jump.
V is provided by polymer matrix for diffusion.
By using Equation (1.10) in Equation (1.11) to obtain Equation (1.12) about
diffusion of a solute in a polymeric matrix.
𝐸

𝐷 = 𝐷0 𝑒 −𝐾𝑇 𝑒

−

𝛾[𝑊𝑠 𝑉𝑠 +𝑊𝑝 𝜉𝑉𝑝 ]
𝑉𝐹𝐻

(1.12)

Ws and Wp are the weight percentage of drug or polymer matrix.
Vp and Vs are the embedded volume of matrix and drug.
VFH is average hole of free volume.
E is the attraction energy between the molecules.
K and T are the Boltzmann’s constant and absolute temperature.
ξ is the ratio of solvent to polymer jumping units.
However, a modified equation, in copolymer media, of molecular migration in
polymer matrix was suggested by Duda and Zelinsky at 1992 [20].
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𝐷 = 𝐷0 𝑒

−

𝐸
𝐾𝑇

𝑒

−

𝛾[𝑊𝑠 𝑉𝑠 +𝑊𝑝 (𝑊2𝑎 𝜉𝑉2𝑎+𝑊 𝜉𝑉2𝑏) ]
2𝑏
𝑉𝐹𝐻

(1.13)

V2k (k is for either a or b) is defined as the specific volume of block k in the copolymer at
0 K; and W2k (k is for either a or b) is defined as the weight fraction of block k in the
copolymer. When polymer matrix is homo-polymer, W2a is equal to zero and W2b is equal
to equation 1.12. The Duda-Zelinsky equation reduces to Vrentas-Duda equation.

1.2.7 Partition Coefficient
The term, partition coefficient, is the ratio of a compound in a mixture of two immiscible
phases in equilibrium so as to measure the different solubility of the compound in these
two phases (Equation 1.14). Kow is the ratio between solution of octanol and water.
𝑠𝑙𝑜𝑢𝑡𝑒 𝑢𝑛−𝑖𝑜𝑛𝑖𝑧𝑒𝑑

log 𝐾𝑜𝑤 = log{ 𝑠𝑙𝑜𝑢𝑡𝑒𝑜𝑐𝑡𝑎𝑛𝑜𝑙
𝑢𝑛−𝑖𝑜𝑛𝑖𝑧𝑒𝑑 }

(1.14)

𝑤𝑎𝑡𝑒𝑟

In pharmacology, the partition coefficient strongly affects how easily the drug can
reach its intended target in the body, how strong an effect it will have once it reaches its
target, and how long it will remain in the body in an active form [20]. Specifically, for a
drug to be percutaneously absorbed, normally it must first pass through lipid bilayers of
corneocytes in the outermost layer (SC) of the epidermis. Hence, the Kow of diffusant
cannot be too small to penetrate lipid bilayers.
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CHAPTER 2
MATERIALS AND METHODS

2.1 Materials
The research material, considered in this study, is a commercial topical anesthetics patch,
SYNERA, which combines amide (lidocaine) and ester (Tetracaine) local anesthetic for
use on intact skin to provide local dermal analgesia for superficial venous access and
superficial dermatological procedures such as excision, electrodessication and shave
biopsy of skin lesion. The structure of SYNERA is shown in Figure 2.1. Table 2.1 presents
the basic information of SYNERA.

Figure 2.1 Synera patch not only includes drug reservoir and other common layers of
transdermal delivery patches, but also includes CHADD heating element layer which uses
chemical reaction to create extra temperature gradient instead of using drug vehicles for
drug diffusion enhancement.
Source: Crank, J., The mathematics of diffusion (2nd Ed.). 2-12, 46-47, 1975.
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Table 2. 1 Basic Information of SYNERA
Featured Indication
Surface anesthetic for minor dermatological procedures in adults and needle punctures
of the skin in adults and children ≥3 years of age
Mechanism of Action
Local anesthetic agent blocks voltage-gated sodium channels
Dosage and Administration
Doses per patch
70 mg/70 mg
Patch size
8.5cm x 6.0cm
Drug cover area
10cm2
Route of administration
Dermal (topical application)
Application site
Normal intact skin
Application time
30 min
Number of simultaneous
1–4 (maximum 4 per 24 h)
plasters (adults)
Number of simultaneous
1–2 (maximum 2 per 24 h)
plasters (children)
Mean Peak Plasma Concentration Following Dermal Application for 30 min of Two
Plasters Simultaneously
Number of SYNERA Patches
1
Age Range (yr)
18- 65
Application Time (min)
30
Drug Content (mg)
Lidocaine 70 /Tetracaine 70
Estimated Amount Absorbed (mg)
Lidocaine/Tetracaine 1.7/1.6
Cmax (ng/mL)
Lidocaine/ Tetracaine 1.7/0.9
Most Frequent Treatment-Related Adverse Events of Mild to Moderate Intensity
in Clinical Trials
Erythema, oedema, pruritus, burning sensation
Partition Coefficient of Octanol/Water
Lidocaine
182 at pH 7.3
Molecular Weight

Tetracaine
5370 at pH 7.3

Lidocaine
234.34 g/mol

Tetracaine
264.363 g/mol
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Although two local anesthesia agents, Lidocaine and Tetracaine, are formulated
by eutectic methods, eutectic mixture is not a crystal but a liquid. This is because the
melting point of this eutectic mixture is lower than room temperature. Hence, unlike other
solid forms of anesthetic agents, SYNERA does not need diffusion vehicle for transdermal
drug delivery in order for it to increase the drug concentration in the drug reservoir layer.
These two special factors, liquid eutectic mixture and thermal enhancer, remarkably
increase the drugs’ absorption ability and minimize the action time of patches so as to avoid
many side effects, such as skin allergy, from drug delivery for long durations.

2.2 Methods
2.2.1 Parameters Switching
In the commercial FEA software, ANSYS 15.0, there is no mass diffusion package.
Therefore, the author has used thermal analysis package instead of mass diffusion. The
reasons for this implementation will be explained in the subsection.
2.2.1.1 Steady-State Diffusion

Fick’s first law introduces the theory of diffusion flux,

J (kg/m2·s), which is the rate of mass concentration transfer through a given surface,
Equation (1.2), per unit time. Similarly, heat flux or thermal flux, q (J/ m2·s) is the rate of
heat energy transfer through a given surface, per unit time, Equation (2.1). Comparing
Equation (1.2) with Equation (2.1), it is easily understood that mass flux and heat flux
separately relate to concentration or temperature gradient; and also, D and k are the
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diffusion coefficient of different transfer equations.
𝑑𝑇

q = −k 𝑑𝑥

(2.1)

q is the heat flux (J/ m2 s).
k is the thermal conductivity (J/m·K·s).
T is absolute temperature (K).
x is distance of temperature gradient (m).
2.2.1.1 Transient Diffusion In Fick’s first law, flux is a constant which will not change
with time; it is called steady- state diffusion. In the same situation, heat flux is also constant.
However, to reach steady state will require some time. Therefore, Fick’s second law,
Equation (1.5), was introduced to demonstrate the relationship between time and flux for
transient diffusion analysis. Also in the heat transfer analysis, there are similar equations
for energy transfer at transient situation, for example, Equation (2.2).
𝜕𝑇
𝜕𝑡

𝑘

= 𝜌𝑐 ∇2 𝑇
𝑝

(2.2)

k is the thermal conductivity (J/m·K·s).
T is absolute temperature (K).
𝜌 is the density (kg/m3).
𝑐𝑝 is the specific heat capacity (J/(kg·K).
Based on the above comparison, except for some differences between parameters,
the form of the two transfer equations are same. Therefore, the use of heat transfer analysis,
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instead of mass diffusion analysis, is viable whether steady-state or transient situation. The
parameter switch is shown in Table 2.2.

Table 2.2 Parameter Switching

Thermal

Mass

Heat
Flux

Conductivity Temperature Density

Heat
Capacity

J/ m2 s

J/m·K·s

K

kg/m3

J/kg·K

Mass
Flux

Diffusivity

Concentrati

Density

Heat
Capacity

1

1

on
kg/m2·s

m2/s

kg/m3

2.2.2 Finite Element Model
This study uses 10 layers in the form of brick and mortar geometry to simulate the twodimensional (2D) geometry of the SC (Figure 2.2). Element type is 4 nodes of two
dimension element, PLANE 55, for thermal analysis. Based on Table 2.2, the conductivity
can be directly replaced by diffusivity (D); and also for transient analysis, specific heat
capacity (Cp) and density (𝜌) are equal to one; moreover, the initial concentration is equal
to 70 kg/m3 for each anesthetic agents. For the shape of the finite element model, the lipid
layer between two corneocytes (S) is equal to 0.1 micrometer; and also the width (d) and
height (h) of corneocytes are 40 micrometer and 1 micrometer, respectively; moreover, the
length (ls) of two lipid pathway in y direction is equal to 10 micrometer.
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Figure 2.2 Geometric Shape of Brick and Mortar Model

2.2.3 Theoretical Calculations of Diffusion Parameters
Transdermal diffusion is not totally like simple mass diffusion, such as diffusion of
hydrogen through metal. This is because, when drug molecules migrate between lipid
media, molecular distribution should be considered first, which means some molecules will
dissolve in liquid so that these molecules cannot pass through the SC even with enough
diffusion time. Hence, the solubility between transfer media and drug will be considered
(The partition ratio of octanol and water is to estimate distribution phenomenon).
2.2.3.1 Maximum Flux Determination

The steady-state diffusion of a drug across the

skin may be described by Fick’s first law, Equation (1.2). In this situation, Fick’s first law
can be manipulated by considering solubility between stratum corneum and drugs [21].
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𝐷

𝐽𝑚𝑎𝑥 = ( ℎ ) ∙ 𝐾𝑠𝑐/𝑣 ∙ 𝐶𝑣,𝑠𝑎𝑡 = 𝑘𝑝 ∙ 𝐶𝑣,𝑠𝑎𝑡

(2.3)

Jmax (kg/m2 s) is the maximum drug flux when the system reaches steady- state. D (m2/s) is
its diffusion coefficient in the stratum corneum (SC).
KSC/v is the drug's SC-vehicle partition coefficient.
h is the length of lipid pathway taken by the penetrant through the SC.
Cv,sat ( kg/m3) is saturated concentration of the drug in the vehicle.
kp (m/s) is the permeability of drug molecule (In this study, it can be directly calculated by
Equation (1.1)).
Comparing Equation (2.3) with Fick’s first law, the diffusion coefficient of
transdermal diffusion is manipulated to DKSC/v. By using permeability (kp) in Equation
(2.3), the new diffusion coefficient will relate to permeability as in Equation (2.4). The new
diffusion coefficient Ds will be used for FE model.

𝐷𝑠 = 𝐾𝑝 ∙ ℎ

(2.4)

2.2.3.2 Permeability Determination The author has already described Potts & Guy
equation, Equation (1.1), for permeability coefficient (kp) of each drug across the skin from
aqueous solution. For calculating the corrected permeability coefficient (Kpcorr), the
following Cleek and Bunge Equation (2.5) will be used for highly lipophilic species for
which viable epidermis can contribute to rate-control [22].
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𝑘𝑝𝑐𝑜𝑟𝑟

𝑘𝑝
𝑘𝑝 ∙√𝑀𝑊
1+
2.6

(2.5)

MW is the drug’s molecular weight. Therefore, if the diffusion pathway length (h)
is calculated as in Figure 2.2, permeability and diffusion coefficient of each drug can be
calculated. The results are shown at Table 2.3. The diffusion pathway length comes from
10 layers in the FE model (h=101μm).
Table 2.3 Diffusion Coefficient of FE Model
Permeability kp (m/s)
Lidocaine
8.3E-9(m/s)

Tetracaine
6.02E-8(m/s)

Diffusion Coefficient Ds (m2/s)
Lidocaine
8.383E-13(m2/s)

2.2.3.3 Lag Time

Tetracaine
6.08E-12(m2/s)

The term of time-lag is the period between closely related events. In

this study, anesthetic agents, lidocaine and tetracaine, should transfer across the epidermis
layer so as to reach the nerve cells of the dermis layer. Although, Fick’s first law can be
used to predict the maximum flux of diffusion, the value of flux always changes with
diffusion time. This is because the concentration gradient between two sides of a membrane
is not always constant (Figure 2.3). Based on Figure 2.3, the changing concentration with
increasing time is not linear before the concentrate penetrates the entire thickness of the
membrane. Hence, the time of concentration, or flux, required to reach stead state is called
the lag time (tL) [22]. The lag time for all FE model results are calculated by extrapolation
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of the steady-state portion of the mass accumulation curve to the time axis. Lag time is
related to the thickness of the skin, or length of diffusion pathway when geometry of media
is irregular shape such as twist lipid pathway, and the diffusion coefficient. The equation
for lag time is described by Equation (2.6).
ℎ2

𝑡𝐿 = 6𝐷

𝑠

(2.6)

Figure 2.3 shows the changing processes of the concentration gradient with increasing
time. Concentration gradient is not linear before concentration reaches the other side of the
membrane at t3. After t3, the concentration gradient is linearly decreasing.
2.2.3.4 Effect of Temperature

In the experimental transport of drugs through cell

membrane, the temperature should be strictly controlled since temperature can increase the
mobility of diffusion molecules. Also the permeability of drug increases significantly as
the experimental temperature is increased in increments of approximately 7 °C [23]. It is
observed that the apparent permeability and temperature are related by an exponential
relationship that conforms to the Arrhenius equation. In this case, the permeability of
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diffusant may be expressed as following equation.
𝑃𝑎𝑝𝑝 =

𝐷𝑇 ×𝐾
ℎ

(2.7)

where Papp is the apparent permeability which is from Potts & Guy equation; K is the
partition coefficient between media and diffusants; h is the length of the pathway.
Combining Equation (2.7) and Arrhenius equation, the new equation will be obtained.
𝑃𝑎𝑝𝑝 =

𝐷0 ×𝑒 −𝐸𝐴 /(𝑘𝑇) ×𝐾
ℎ

(2.8)

Assuming that the partition coefficient and length of diffusion pathway remain
constant over the range of temperature studied, the following relationship can be derived
as in Equation (2.8) [23].
−1

𝑃𝑎𝑝𝑝 ∝ 𝑒 𝑇

(2.9)

This suggests that the apparent permeability of drugs increases exponentially with
temperature. A plot of logarithm of apparent permeability versus absolute temperature will
yield a linear relationship such as in Figure 2.4. In this study, a heating layer is also added
to topical patches to increase the skin temperature up to 40 °C. Hence, the relationship
between permeability of drugs, Lidocaine and Tetracaine, and temperature will be plotted.
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Figure 2.4 A plot of lnP versus 1/T for five different temperatures, viz., 23°C, 30°C, 37°C,
45°C, and 52°C, were utilized in individual permeation experiments. Four different
diffusants transfer across porcine buccal mucosa.
Source: Kulkarni, U.P., Mahalingam, R., Li, X., Pather, I. and Jasti, B., Effect of Experimental Temperature
on the Permeation of Model Diffusants Across Pocine Buccal Mucosa, AAPS PharmSciTech, Vol. 12, No.
2, DOI: 10.1208/s12249-011-9624-z, 2011.

2.2.3.5 Mass Absorbed. The flux and permeability coefficient allow an exposure
assessment over time in steady-state condition [24]. When Fick’s first law of diffusion is
applied, Kp is constant over the range of concentration. Therefore, in order to characterize
the quantity absorbed (M), some risk assessors have to be integrated over Kp by multiplying
the chemical concentration (C) (i.e. the flux: J = Kp x C), the exposed surface (S) and the
exposure time (t):
dM = J × S × dt = Kp × C × S × dt

(2.10)

From Equation (2.9), the amount of absorbed mass increases with increasing
permeability when the area and diffusion time are assumed to be constant. Hence, the
−1

quantities absorbed is directly dependent on 𝑒 𝑇 .
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However, in this study, the FE model is only a two dimensional model. Also the
time-lag should be considered. Therefore, the new equation derived from Equation (2.9) is
the following.
𝑑𝑀
𝑑𝑆

= 𝐽 × (𝑡 − 𝑡𝐿 )

(2.11)

When active time is bigger than time-lag (tL), Equation (2.10) can be used for
prediction of permeation mass. This is because, after tL, the diffusion process is going to
be steady-state.
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CHAPTER 3
RESULTS AND DISCUSSION

3.1 Maximum Flux and Lag Time
In steady-state, the maximum flux, Jmax, should be first considered. FE results compared
with analytical results for flux (Equation (2.4)) and for time lag (Equation (2.6)) are
presented in Table 3.1. After lag time tL, the diffusion system reaches steady state at the
same location. For estimating the lag time across ten layers in the FE model, Equation (2.9)
is used to plot the mass accumulation curve; and also, the ending time of diffusion process
is 4000s (Figure 3.1) because analytical results of time-lag of lidocaine is 2028s. Hence,
the processing time of Tetracaine is 500s (Figure 3.2) because analytical lag time is 280s.
Table 3.1 Analytical and FE Results (Flux and Lag Time)
Analytical results

FE results

0.581E-6

0.560E-6

2028

2020

4.214E-6

4.07 E-6

280

272.5

Lidocaine
SS Flux (kg/m2 s)
Time lag (s)
Tetracaine
SS Flux (kg/m2 s)
Time lag (s)
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Figure 3.1 shows that the cumulative permeation curve of Lidocaine per unit area has two
portions. The initial portion of the curve represents non-steady state diffusion, and linear
portion corresponds to steady state diffusion. Therefore, if extending steady state line
intersects with time axis, the lag time will be gained. The intersection point is between
2040s and 2000s.

Figure 3.2 shows cumulative permeation curve of Tetracaine. This curve also has two
portions, similar to the results for Lidocaine. Extending steady state line intersects with
time axis to gain the intersection point which is between 275s and 280s. Hence, the FE
result of lag time when Teracaine passes through ten layer-model is 272.5s.
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3.2 Concentration Distribution
The concentration distribution in the lipid layers of the 10 layers stratum corneum model
is depicted in Figure 3.3 at 1800s. The concentration of Lidocaine (Figure 3.3 (A)) in the
bottom of the model is not steady state because diffusion time is smaller than lag time (tL=
2028s). However, Tetracaine (Figure 3.3(B)) is a good approximation for the steady state.
A path was created at location 101µm with the lipid diffusion pathway and the
concentration distribution across the SC is shown in Figure 3.4.

Figure 3.3 shows the contour plots of concentration distribution. (A) Contour plot of
concentration distribution of Lidocaine. Color signifies concentration ranging from 0.1124
(blue) to 70 (red). Based on the differences between adjacent colors, the range of color
(blue) is non-steady state. (B) Contour plot of concentration distribution of Tetracaine.
Color signifies concentration ranging from 27.06 (blue) to 70 (red). Based on the
differences between adjacent colors, diffusion of Tetracaine is a good approximation for
steady state.
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Figure 3.4 shows the concentration distribution along with the lipid pathway. The length
of lipid pathway is 101 µm at ten layers FE model. After 1800s diffusion, concentration
distribution of Tetracaine decreases with increasing distance and is almost a straight line.
However, after 1800s, the concentration distribution of Lidocaine does not reach steady
state.

3.3 Absorbed Mass
The SYNERA heating component generates a mild warming that is intended to increase
the skin temperature from 37 °C to 40 °C so as to enhance the diffusion of the local
anesthetic agents. However, the permeability is calculated by Equation (1.1), which is
apparent permeability of diffusants at room temperature (25 °C). Therefore, the
permeability changes with temperature should be considered.
Clinical results show that 1.7 gram Lidocaine and 1.6 gram Tetracaine are
absorbed by the skin after 30min (1800s) [Highlights of Prescribing Information]. In the
FE model, the distance of diffusion pathway can be ignored. This is because the diffusion
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depth will not be considered and the author is only interested in the number of molecules
absorbed by the skin. Therefore, the time-lag can also be ignored. Equation (2.9) can be
directly used for analytical results (shown in Table 3.2). The FE results are plotted in Figure
3.5 and Figure 3.6.
Table 3.2 Absorbed Mass per Unit Area
Absorbed mass per unit
area (kg/m2)
Analytical results
Lidocaine

Tetracaine

1.0458E-3

FE results

1.14E-3

Analytical results

7.578E-3

FE results

6.52E-3

Figure 3.5 shows the curve of absorbed mass of Lidocaine per unit area. The slope of this
curve decreases with time since the concentration gradient decreases with processing time.
The black line corresponds to 1.14E-3 kg/m2 of Lidocaine going into skin after 30 min.
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Figure 3.6 shows the curve of mass absorbed of Tetracaine per unit area. The slope of this
curve decreases with time since the concentration gradient decreases with processing time.
The black line shows 7.578kg/m2 Tetracaine going into the skin after 30 min.
In this study, the effects of temperature are not considered since thermal analysis
has been replaced by mass diffusion analysis. However, based on the results in Table 3.2,
the absorbed mass of Lidocaine for 10cm2, similar to the size of Synera drug, is 1.14mg
which is smaller than 1.7mg. This is because the extra temperature from heating layer of
the Synera patch increases the mobility of Lidocaine particles so as to increase the
penetration rate of Lidocaine. However, the 7.578mg Tetracaine is absorbed by the skin,
which is much bigger than clinical experiments. This may be because there is a layer
between the skin and the drug reservoir for limiting the release of Tetracaine.
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CHAPTER 4
CONCLUSIONS

The objective of this thesis was to build a transdermal finite element model which can
estimate results of transdermal diffusion experiments. Since the common transdermal
experiments needs long time to prepare, by mimicking the brick and mortar structure, a
successful simulation of the stratum corneum lipid pathway accomplished the objective.
FE model was used in mechanics and heat flow analysis. A method to use a commercial
FE package (ANSYS) to solve a real transdermal diffusion problem is presented here. The
method has been validated by comparing FE model results with results for real local
transdermal patches for which analytical solutions exist. Although scientists believe that
percutaneous penetration of polar and ionized compounds occurs not only through the lipid
pathway route (intercellular) but also via a transcellular route that is through the
corneocytes [25], the intercellular route is the main pathway for high lipophilic molecules.
The permeability of the intercellular route can be easily calculated by Potts & Guy equation
(Equation (1.1)) without experimental data, which correlates the skin permeability to solute
molecular weight and octanol-water partition coefficient. However, the main disadvantage
of using Potts & Guy equation is that the relationship between permeability and
temperature (Equation (2.8)) cannot be represented by FE model. This is because in this
study, parameters of the thermal transfer were replaced by mass diffusion parameters (Table
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2.2). The stratum corneum model described here are two dimensional (2-D). Using three
dimensional (3-D) will be a more realistic approach to represent the stratum corneum
structure. Advantages of three dimensional model over two dimensional model are
unknown. This is because although 3-D model uses more elements to increase realism, it
always repeats same geometric structures of 2-D model. Wang [26] already compared 2-D
and 3-D SC model topology. The same tortuosities of two models was found so that Wang
argues that 2-D representation of the stratum corneum is adequate for the purpose of
transdermal diffusion modeling.
For accuracy and realism, the use of a biological image is the best option to
generate the SC topology, especially to observe the concentration distribution in any
location and any time [27]. But in this study, good approximate flux and time lag results
were estimated by a regular brick and mortar geometry. Therefore, regular brick and mortar
geometry can be used instead of the more complicated but realistic irregular geometry.
For reducing computational time of 2-D stratum corneum model, different element
types were used for different results. The element link 33 was used to replace element plane
55 for concentration distribution contour-plot. This is because using element link 33 can
remarkably decrease the amount of elements. But link element can be calculated for flux.
The next step in this work is to utilize experimental results, time lags and
permeability, to evaluate FE results with various sets of diffusivity. The transcellular route
should be considered in situations when FE model deals with hydrophilic compounds.
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